Close Menu

NEW YORK – The Foundation for Innovative New Diagnostics announced on Thursday it has signed a $14.5 million deal with Unitaid to evaluate using next-generation sequencing for diagnosing drug-resistant tuberculosis in low- and middle-income nations.

Over three years, starting in October, the project, called Seq&Treat, will be implemented in Brazil, China, Georgia, India, and South Africa. The project, FIND said, will enable the introduction and adoption of targeted NGS technology for affordable, scalable, and rapid TB drug-susceptibility testing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.